BioCardia Inc (NAS:BCDA)
$ 0.392 0 (0%) Market Cap: 10.53 Mil Enterprise Value: 10.81 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 30/100

BioCardia Inc at LD Micro Microcap Invitational Conference (Virtual) Transcript

Jun 08, 2021 / 08:30PM GMT
Release Date Price: $4.6 (-0.86%)
John Peyton
SRAX, Inc. - Moderator

Hi, my name is John Peyton, Business Development at Sequire, shareholder insight and acquisitions. I'm here to present Dr. Peter Altman, CEO of BioCardia, Inc. BioCardia is a clinical-stage regenerative medicines company that develops therapeutics for cardiovascular disease. The lead candidate is the CardiAMP cell therapy system for treatment of heart failure, and chronic myocardial ischemia, and allogenic cell therapy for cardiac and pulmonary disease. The company is based in San Carlos, California.

Dr. Altman, over to you.

Peter Altman
BioCardia, Inc. - President & CEO

Thank you, John. So BioCardia has been focused on bringing personalized medicine to cell therapy for cardiovascular disease. Our efforts today are extensive. And I'll detail them trying to stay at the top level.

Here's our standard forward-looking statements. And I'm going to drop off the screen just to essentially enable folks to understand our pipeline opportunities here.

So the primary reason to be interested in BioCardia

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot